Abstract:The activation of adaptive antitumor immune response is paramount for improving the long-term antitumor efficiency. Chemotherapy, radiotherapy, and photodynamic therapy (PDT) can induce cell apoptosis and immunogenic cell death (ICD). Subsequently, the exposure or release of damage-associated molecular patterns (DAMPs) caused by ICD can stimulate the immune system to exert an antitumor immune response, recruit the antigen-presenting cells, and activate the adaptive immune responses of T cells. As such, the application of ICD inducers in tumor therapy is of crucial role in improving the therapeutic effects and the survival rate of cancer patients. Recently, accumulating evidence has revealed that nanomaterials-based platforms for cancer treatment could not only achieve controlled drug release in response to stimulation of tumor microenvironment (TME), but also regulate TME to enhance ICD in the tumor. Hence, the construction of ICD effects-based biomedical nanomaterials has sparked tremendous attention. Benefiting from their unique size, biomedical nanomaterials are commonly applied as ICD inducers carriers to target tumor tissue and enhance selective enrichment in the tumor. By taking advantage of their easily modified surface properties and multi-selectivity of raw materials, nanomaterials can also be designed as functionalized carriers with stimulus responses to TME, thereby achieving stepwise and controlled release of ICD inducers. Meanwhile, biomedical nanomaterials are capable of codelivering different components, protecting the payload from degradation and precise controlled release. These abilities enable nanomaterials to amplify the antitumor effects of chemotherapy, radiotherapy, PDT and many other emerging therapies. Of note, a single therapy has been limited by many factors. Chemotherapy and radiotherapy can bring about irreversible damage to normal tissue cells and immune cells. The hypoxic TME limits the function of PDT. On top of that, monotherapy has been also vulnerable to tumor heterogeneity. On this ground, combination therapy has become the prior option for cancer therapy. Furthermore, the synergistic of these therapies with immune checkpoints, immunosuppressive factors, immune adjuvants, immune cells and other strategies that can enhance ICD has been extensively estimated. In this paper, we first introduced the generation of the ICD, then emphasized the multifunctional roles of nanomaterials in inducing ICD and regulating the microenvironment of tumor cells. Ulteriorly, the tremendous potential, challenges and development trends of nanomaterials in therapeutic effects of ICD have been expounded and concluded. Finally, to make better use of nanomaterials and accelerate clinical transformation in the future, it is imperative to further explore the transfer efficiency, degradation and metabolism of nanomaterials, and propose a more specific and in-depth understanding of the molecular mechanism of ICD.

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Nanomaterials: leading immunogenic cell death-based cancer therapies

Engineering Immunogenic Cell Death with Nanosized Drug Delivery Systems Improving Cancer Immunotherapy.

Applying Nanotechnology to Boost Cancer Immunotherapy by Promoting Immunogenic Cell Death

Multifunctional Nano‐Biomaterials for Cancer Therapy Via Inducing Enhanced Immunogenic Cell Death

Nanomedicine-mediated Immunogenic Cell Death and Its Combination with Immune Checkpoint Blockade Therapy

Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy

Nanoengineered Targeting Strategy for Cancer Immunotherapy

Promotion of ICD Via Nanotechnology.

Biomedical Nanomaterials for the Enhancement of Immunogenic Cell Death-Based Cancer Immunotherapy

Nanomedicine-mediated Regulated Cell Death in Cancer Immunotherapy.

Nanoscale Metal–organic Framework-Mediated Immunogenic Cell Death Boosting Tumor Immunotherapy

Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials

Combination Cancer Immunotherapy Of Nanoparticle-Based Immunogenic Cell Death Inducers And Immune Checkpoint Inhibitors

Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches

Nanomedicine-induced Programmed Cell Death Enhances Tumor Immunotherapy

Role of Nanoparticle-Mediated Immunogenic Cell Death in Cancer Immunotherapy

Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy

Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy

Current status of nanoparticle-mediated immunogenic cell death in cancer immunotherapy